Biotech Startups

Oncoliq develops early cancer detection technology that combines molecular biology and machine learning to offer a non-toxic, non-invasive, and low-cost diagnostic approach. The company operates in the cancer diagnostics field.

2 investors

Mereo BioPharma is a rare disease drug developer that funds and advances novel therapeutic candidates not progressed by their originating pharmaceutical or biotech companies, with lead programs in osteogenesis imperfecta and Alpha-1 Antitrypsin Deficiency-associated Lung Disease. It operates a capital-efficient model, retaining regional development rights while forming strategic partnerships, and collaborates with patient communities in the rare disease space.

2 investors

OncoPatch develops a non-invasive medical patch that delivers low-energy beta therapy to treat non-melanoma skin cancers, including basal and squamous cell carcinomas. The single-application treatment is administered in a physician's office and targets cancer cells while sparing healthy tissue.

2 investors

OncoRevive develops a multiomics blood test combining nanotechnology, cancer biology, and AI to detect and monitor cancer in less than 2 hours at a fraction of current costs. The test is designed for healthcare providers, hospitals, and pathology labs seeking rapid, comprehensive same-day cancer diagnostics.

2 investors

Oncostellae is a biotech company developing novel JAK inhibitors for the treatment of inflammatory bowel disease and cancer, with a focus on local, gut-restricted therapies that minimize systemic toxicity.

2 investors

Oncosyne develops functional biology tools and preclinical models for cancer drug development and patient stratification, serving oncology drug developers and precision medicine researchers.

2 investors

Clinical-stage oncology company developing cancer treatments

2 investors

OneChain Immunotherapeutics is a clinical-stage biotech developing CAR-T cell therapy candidates as treatments for oncological diseases. It is a spin-off from the Josep Carreras Leukemia Research Institute and ICREA, based on research led by Dr. Pablo Menéndez's team.

2 investors

Onego Bio produces Bioalbumen®, a fermentation-derived ovalbumin protein powder that replicates egg white functionality for large-scale food manufacturing without animal agriculture. The product serves food producers seeking sustainable, price-stable, and supply-resilient egg protein alternatives.

2 investors

ONWARD Health Research is a technology and services company offering tech-enabled clinical trials through its ONWARDAccess platform, which is customized to match clinical trial protocols. It serves the pharma/biotech, medical device, and digital health sectors, with a focus on the Asia-Pacific region.

2 investors

Oorja Bio is a biotechnology company developing therapies focused on fibrotic disease, aiming to repair, reverse, and remodel fibrosis.

2 investors

OpenProtein.AI offers protein language models and AI infrastructure for protein engineering, covering de novo sequence design, variant effect prediction, in silico screening, and training specialized models on proprietary data. Accessible via a no-code GUI and APIs, it serves biology and computational research teams working in protein design and drug discovery.

2 investors

OpenBiome Foundation advances microbiome-targeted therapies for serious conditions like Clostridioides difficile through partnerships, innovation funding, and open-access research tools. The organization works to expand patient access to microbiome treatments while accelerating scientific discovery in the field.

2 investors

The page announces the launch of a new fintech arm called CapForce. No further detail about the company's core business is provided on the page.

2 investors

2 investors

Optegra operates dedicated private eye hospitals offering ophthalmic diagnostics, cataract and laser eye surgery, and aftercare delivered by NHS-trained consultant surgeons. It serves private and NHS eye-care patients, providing free video or telephone consultations and personalised treatment plans.

2 investors

OpticSurg is a healthcare software startup building mixed reality tools for surgical operations and frontline healthcare workers, with the goal of reducing complications and expanding provider capacity. It focuses on serving providers in vulnerable and underserved communities.

2 investors

OraLiva develops an AI-powered, non-invasive oral cancer test designed to detect cancer early during routine dental visits, using single-cell analysis and microfluidic technologies. The company is advancing a point-of-care diagnostic device for dental networks, building on its current lab-developed platform.

2 investors

Orange Grove Bio is a biotech venture firm that builds and backs cell therapy and immuno-oncology companies, forming subsidiary companies (subcos) such as Ipinovyx and DomainOne Therapeutics. It operates in the biopharmaceutical and life sciences investment space.

2 investors

Orbion provides a computational platform for protein engineering that characterizes sequences, ranks stabilizing mutations, predicts construct expression, and generates experimental protocols to filter designs before lab synthesis. The platform serves biotechnology researchers and protein engineers working to optimize protein candidates for expression and function.

2 investors

Orbit Genomics is a precision healthcare company built on OrbiSeq, an AI-enabled genomics platform that analyzes short tandem repeats (STRs) alongside single nucleotide polymorphisms to detect disease biology. Its lead product is a blood test for diagnosing early-stage lung cancer in patients with indeterminate pulmonary nodules, with a pipeline extending across other therapeutic areas.

2 investors

Orchestra BioMed develops medical device products and uses a partnership-based model, collaborating with medical device companies to commercialize them globally. It operates in the medical device and biomedical industry.

2 investors

Organicin Scientific develops the CinThesis platform for applications in animal health and aquaculture sectors. The company focuses on translating its technology into products for these life science-related markets.

2 investors

Organovo develops regenerative medicine therapies using bioprinting technology to treat serious liver diseases. The company serves the pharmaceutical and biotech sectors with innovative therapeutic approaches based on decades of leadership expertise in life sciences.

2 investors